Programme

Monday, September 2

08.00 – 10:00

Registration

10:00-10:30

Opening

Jan Konvalinka (Director of IOCB Prague), Milan Pospíšil (Rector of UCT Prague), Eva Zažímalová (President of the Czech Academy of Sciences), Her Excellency Anna Azari (Ambassador of Israel to the Czech Republic)

10:30-11:10

Petra Ménová, UCT Prague, Czech Republic

How are new drugs born?

 

11:10-11:50

Deborah Fass, Weizmann Institute of Science, Rehovot, Israel

Structures of mucin glycoproteins inspire molecular methods for modulating mucosal functions

11:50-12:30

Milan Vrábel, IOCB Prague, Czech Republic

Chemical engineering of cell surfaces for cancer immunotherapy

12:30-13:50

Lunch

13:50-14:30

Marek Šťastný, Medical Department, Bristol-Myers Squibb, Czech Republic

Cancer immunotherapies based on anti-PD1: clinical perspectives and challenges

14:30-15:10

Stella Vukelic, AbbVie, Ludwigshafen, Germany

Molecular obesity – An addiction in drug discovery?

15:10-15:50

Jitka Riedl, Bicycle Therapeutics, Cambridge, UK

Attacking from all angles: EphA2 targeting Bicycle® peptides for precision guided cancer therapy via multiple approaches

15:50-16:20

Coffee break

16:20-17:00

David Margulies, Weizmann Institute of Science, Rehovot, Israel

Detecting proteins and protein-inhibitor interactions with ‘turn-on’ fluorescent molecular probes: design principles and applications in medical diagnosis, cell imaging and drug discovery

17:00-17:40

Andrea Brancale, UCT Prague, Czech Republic

Kick-start new drug design projects using computer-aided drug design

19:00

Welcome party

Tuesday, September 3

07:30 – 09:00

Registration

09:00-09:40

Peter H. Seeberger, Max Planck Institute of Colloids and Iterfaces, Potsdam, Germany
Freie Universität, Berlin, Germany

Synthetic glycans as basis for vaccines, therapeutic antibodies and diagnostics

09:40-10:20

Christoph Rademacher, University of Vienna, Austria

Cell-specific targeted delivery of therapeutics

10:20-10:50

Coffee break

10:50-11:30

Frank Wagner, Charité, Berlin, Germany

Focus on early clinical trials

11:30-12:10

Oliviana Calin-Eller, E. Blum & Co. AG, Zurich, Switzerland

Patents: Why? What? How?

12:10-12:50

Valery Khrizanovsky, Weizmann Institute of Science, Rehovot, Israel

Senescent cells in aging and age-related disease: the good, the bad and the ugly

12:50-14:10

Lunch

14:10-15:40

Spin-offs: roundtable discussion

Panelists: Peter H. Seeberger, Frank Wagner, Christoph Rademacher, Andrea Brancale, Valery Khrizanovsky, Oliviana Calin-Eller
Host: Aleš Vlk

15:50-17:30

Poster session + refreshments

Wednesday, September 4

07:30 – 09:00

Registration

09:00-09:40

Stephan Bachmann, F. Hoffmann-La Roche Ltd., Basel, Switzerland

Catalysis as key technology for the synthesis and scale-up of APIs and their intermediates

09:40-10:20

Camille Correia, Merck Electronics KGaA, Darmstadt, Germany

Modular continuous automation for laboratories and production

10:20-10:50

Coffee break

10:50-11:30

Martina Benešová-Schäfer, German Cancer Research Center, Heidelberg, Germany

Pharmaceutical radiochemistry in modern nuclear medicine

11:30-12:10

Sima Lev, Weizmann Institute of Science, Rehovot, Israel

Triple-negative breast cancer: heterogeneity and targeted therapy

12:10-12:50

Kateřina Vávrová, Faculty of Pharmacy Hradec Kralove, Charles University, Czech Republic

Ceramides in the skin: extraordinary lipids for an extraordinary barrier

12:50-14:00

Lunch

14:00-18:00

Prague city tour

18:00

Social evening – Karolinum

Thursday, September 5

07:30 – 09:00

Registration

09:00-09:40

Jan Konvalinka, IOCB Prague, Czech Republic

Chemical-biology tools in drug development

09:40-10:20

Daniela Angst, Novartis, Basel, Switzerland

Remibrutinib, a covalent BTK inhibitor with best-in-class selectivity: discovery and clinical results

10:20-10:50

Coffee break

10:50-11:30

Roy Bar-Ziv, Weizmann Institute of Science, Rehovot, Israel

„Artificial Cells“ on a chip

11:30-12:10

TBA

12:10-13:30

Lunch

13:30-14:10

Gideon Schreiber, Weizmann Institute of Science, Rehovot, Israel

Reversing protonation of weakly basic drugs greatly enhances intracellular diffusion and decreases lysosomal sequestration

14:10-14:50

Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel

Overcoming resistance of lung cancer to tyrosine kinase inhibitors

14:50-15:30

Richard Clarkson, Cardiff University, UK

Targeting cells responsible for metastatic disease

15:30-18:00

Excursions: UCT Brewery, IOCB labs

Friday, September 6

07:30 – 09:00

Registration

09:00-09:40

Pavlína Řezáčová, IOCB Prague, Czech Republic

Structure-assisted design of enzyme inhibitors

09:40-10:20

Igor Ulitsky, Weizmann Institute of Science, Rehovot, Israel

Therapeutic targeting of RNA molecules

10:20-10:50

Coffee break

10:50-11:30

Jitka Palich Fučíková, Sotio Biotech Department of Immunology, 2nd Medical school, Charles University, Czech Republic

The role of immune system in cancer therapy

11:30-12:10

Menachem Rubinstein, Weizmann Institute of Science, Rehovot, Israel

Directing viral vectors to specific cell types for oncolytic virotherapy and in vivo gene therapy

12:10-13:30

Lunch

13:30-14:10

Michal Tichý, IOCB Prague, Czech Republic

Kinase Inhibitors: From insoluble and promiscuous hit to drug candidate

14:10-14:50

Kvido Stříšovský, IOCB Prague, Czech Republic

The elusive mechanisms of unexpected regulators of inflammatory and growth factor signalling

14:50-15:00

Closing, best poster award